• Coronary artery disease · May 2017

    Multicenter Study Comparative Study

    Impact of chronic statin therapy on clinical presentation and underlying lesion morphology in patients undergoing percutaneous intervention: an ADAPT-DES IVUS substudy.

    • Tadayuki Kadohira, Gary S Mintz, Cristiano F Souza, Bernhard Witzenbichler, D Christopher Metzger, Michael J Rinaldi, Ernest L Mazzaferri, Peter L Duffy, Giora Weisz, Thomas D Stuckey, Bruce R Brodie, Aaron Crowley, Ajay J Kirtane, Gregg W Stone, and Akiko Maehara.
    • aClinical Trials Center,Cardiovascular Research Foundation bNew York-Presbyterian Hospital/Columbia University Medical Center, NewYork, New York cWellmont CVA Heart Institute, Kingsport, Tennessee dSanger Heart & Vascular Institute/Carolinas HealthCare System, Charlotte eReid Heart Center, FirstHealth of the Carolinas, Pinehurst fLeBauer-Brodie Center for Cardiovascular Research and Education/Cone Health, Greensboro, North Carolina gThe Ohio State University Wexner Medical Center, Columbus, Ohio, USA hShaare Zedek Medical Center, Jerusalem, Israel iFederal University of São Paulo, São Paulo, Brazil jHelios Amper-Klinikum, Dachau, Germany.
    • Coron. Artery Dis. 2017 May 1; 28 (3): 218-224.

    ObjectivePrevious intravascular ultrasound (IVUS) studies have not established a relationship between chronic statin use and plaque morphology and composition in patients undergoing percutaneous coronary intervention (PCI). We sought to use pre-PCI grayscale and virtual histology (VH)-IVUS to assess plaque morphology and composition in patients treated with chronic statin therapy compared with patients who were not taking statins before admission and PCI.MethodsIn a prespecified substudy of the Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents study, pre-PCI grayscale and VH-IVUS were performed in 780 patients with 916 culprit and 765 nonculprit lesions.ResultsOverall, 338 patients were treated with chronic statin therapy before admission. Statin-treated patients were older and had a higher prevalence of coronary risk factors. Statin-treated patients were more likely to present with stable angina, whereas non-statin-treated patients more frequently presented with acute myocardial infarction. Grayscale and VH-IVUS findings showed that lesions in statin-treated patients had a smaller plaque burden, but more dense calcium. Statin-treated patients had more calcified thick-cap fibroatheromas (9.2 vs. 3.7%, P=0.0007), but fewer VH-defined thin-cap fibroatheromas (45.2 vs. 56.1%, P=0.001) or plaque ruptures (26.6 vs. 38.4%, P=0.0001). In a propensity-matched population (n=249 in each group), similar results were obtained as regards clinical presentation and grayscale and VH-IVUS findings.ConclusionChronic statin use in patients with coronary artery disease was associated with more stable clinical presentation and IVUS findings consistent with greater lesion stability (fewer VH-thin-cap fibroatheromas and plaque ruptures and more calcified thick-cap fibroatheromas).

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.